EGFR signaling in breast cancer: Bad to the bone

Seminars in Cell and Developmental Biology

Volumn 21, Issue 9, 2010, Pages 951-960

  Foley, John ^a,c   Nickerson, Nicole K ^a   Nam, Seungyoon ^a   Allen, Kah Tan ^a   Gilmore, Jennifer L ^a,b,c,d   Nephew, Kenneth P ^a,c   Riese, David J ^b,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Purdue University   (United States)

Author keywords

Bone metastasis; Epidermal growth factor receptor; Resistance to endocrine therapy; Stem like tumor cells; Triple negative tumors

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FULVESTRANT; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; VIRULENCE FACTOR;

BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL FUNCTION; GENE EXPRESSION; HUMAN; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 78449294111     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2010.08.009     Document Type: Review

References (128)

1. Carney W., Leitzel K., Ali S., Neumann R., Lipton A. HER-2 therapy. HER-2/neu diagnostics in breast cancer. Breast Cancer Res 2007, 9:207.
2. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
3. Jones F.E. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:247-258.
4. O'Donovan N., Crown J. EGFR and HER-2 antagonists in breast cancer. Anticancer Res 2007, 27:1285-1294.
5. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004, 319:1-11.
6. Spector N., Xia W., El-Hariry I., Yarden Y., Bacus S. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res 2007, 9:205.
7. Stern D. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:215-223.
8. Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:259-268.
9. Suo Z., Risberg B., Karlsson M.G., Villman K., Skovlund E., Nesland J.M. The expression of EGFR family ligands in breast carcinomas. Int J Surg Pathol 2002, 10:91-99.
10. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002, 71:67-75.
11. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007, 18:977-984.
12. Wieduwilt M.J., Moasser M.M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008, 65:1566-1584.
13. Zaczek A., Brandt B., Bielawski K.P. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 2005, 20:1005-1015.
14. Campbell M.R., Amin D., Moasser M.M. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010, 16:1373-1383.
15. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887.
16. Riese D.J., Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998, 20:41-48.
17. Wilson K.J., Gilmore J.L., Foley J., Lemmon M.A., Riese D.J. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 2009, 122:1-8.
18. Mill C.P., Chester J.A., Riese D.J. EGFR may couple moderate alcohol consumption to increased breast cancer risk. Breast Cancer (London) 2009, 2009:31-38.
19. Ohtsu H., Dempsey P.J., Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 2006, 291:C1-C10.
20. Shah B.H., Catt K.J. TACE-dependent EGF receptor activation in angiotensin-II-induced kidney disease. Trends Pharmacol Sci 2006, 27:235-237.
21. Bhola N.E., Grandis J.R. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 2008, 13:1857-1865.
22. Daub H., Weiss F.U., Wallasch C., Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996, 379:557-560.
23. Tada H., Sasada R., Kawaguchi Y., Kojima I., Gullick W.J., Salomon D.S., et al. Processing and juxtacrine activity of membrane-anchored betacellulin. J Cell Biochem 1999, 72:423-434.
24. Dobashi Y., Stern D.F. Membrane-anchored forms of EGF stimulate focus formation and intercellular communication. Oncogene 1991, 6:1151-1159.
25. Dong J., Opresko L.K., Chrisler W., Orr G., Quesenberry R.D., Lauffenburger D.A., et al. The membrane-anchoring domain of epidermal growth factor receptor ligands dictates their ability to operate in juxtacrine mode. Mol Biol Cell 2005, 16:2984-2998.
26. Riese D.J., Gallo R.M., Settleman J. Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays 2007, 29:558-565.
27. Lemmon M.A. Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009, 315:638-648.
28. Schulze W.X., Deng L., Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005, 1:0008.
29. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
30. Sorkin A., Mazzotti M., Sorkina T., Scotto L., Beguinot L. Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr974-containing internalization motif. J Biol Chem 1996, 271:13377-13384.
31. Keilhack H., Tenev T., Nyakatura E., Godovac-Zimmermann J., Nielsen L., Seedorf K., et al. Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. J Biol Chem 1998, 273:24839-24846.
32. Tenev T., Keilhack H., Tomic S., Stoyanov B., Stein-Gerlach M., Lammers R., et al. Both SH2 domains are involved in interaction of SHP-1 with the epidermal growth factor receptor but cannot confer receptor-directed activity to SHP-1/SHP-2 chimera. J Biol Chem 1997, 272:5966-5973.
33. Earp H.S., Dawson T.L., Li X., Yu H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 1995, 35:115-132.
34. Wada T., Qian X.L., Greene M.I. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 1990, 61:1339-1347.
35. Gulliford T.J., Huang G.C., Ouyang X., Epstein R.J. Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2. Oncogene 1997, 15:2219-2223.
36. Wang Z., Zhang L., Yeung T.K., Chen X. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell 1999, 10:1621-1636.
37. Hendriks B.S., Wiley H.S., Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. Biophys J 2003, 85:2732-2745.
38. Gilmore J.L., Scott J.A., Bouizar Z., Robling A., Pitfield S.E., Riese D.J., et al. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat 2008, 110:493-505.
39. Levkowitz G., Waterman H., Zamir E., Kam Z., Oved S., Langdon W.Y., et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998, 12:3663-3674.
40. Stern K.A., Place T.L., Lill N.L. EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate. Biochem J 2008, 410:585-594.
41. Willmarth N.E., Baillo A., Dziubinski M.L., Wilson K., Riese D.J., Ethier S.P. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal 2009, 21:212-219.
42. Gilmore J.L., Gonterman R.M., Menon K., Lorch G., Riese D.J., Robling A. Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone. Mol Cancer Res 2009, 7:1714-1728.
43. Joslin E.J., Opresko L.K., Wells A., Wiley H.S., Lauffenburger D.A. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci 2007, 120:3688-3699.
44. Garcia Castro C., Ravina M., Castro V., Salido E.C. Expression of epidermal growth factor receptor (proto-oncogene c-erbB-1) and estrogen receptor in human breast carcinoma. An immunocytochemical study of 70 cases. Arch Gynecol Obstet 1993, 252:169-177.
45. Martinazzi M., Crivelli F., Zampatti C., Martinazzi S. Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma. J Clin Pathol 1993, 46:1009-1010.
46. Newby J.C., A'Hern R.P., Leek R.D., Smith I.E., Harris A.L., Dowsett M. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. Br J Cancer 1995, 71:1237-1242.
47. Schroeder W., Biesterfeld S., Zillessen S., Rath W. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 1997, 17:2799-2802.
48. Ferrero J.M., Ramaioli A., Largillier R., Formento J.L., Francoual M., Ettore F., et al. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 2001, 12:841-846.
49. Pawlowski V., Revillion F., Hebbar M., Hornez L., Peyrat J.P. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000, 6:4217-4225.
50. Ma L., de Roquancourt A., Bertheau P., Chevret S., Millot G., Sastre-Garau X., et al. Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions. J Pathol 2001, 194:413-419.
51. Soares R., Pereira M.B., Silva C., Amendoeira I., Wagner R., Ferro J., et al. Expression of TGF-alpha and EGFR in breast cancer and its relation to angiogenesis. Breast J 2000, 6:171-177.
52. Desruisseau S., Palmari J., Giusti C., Romain S., Martin P.M., Berthois Y. Clinical relevance of amphiregulin and VEGF in primary breast cancers. Int J Cancer 2004, 111:733-740.
53. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
54. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
55. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
56. Da Silva L., Clarke C., Lakhani S.R. Demystifying basal-like breast carcinomas. J Clin Pathol 2007, 60:1328-1332.
57. Korsching E., Jeffrey S.S., Meinerz W., Decker T., Boecker W., Buerger H. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008, 61:553-560.
58. Burness M.L., Grushko T.A., Olopade O.I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. Cancer J 2010, 16:23-32.
59. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
60. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
61. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
62. Viale G., Rotmensz N., Maisonneuve P., Bottiglieri L., Montagna E., Luini A., et al. Invasive ductal carcinoma of the breast with the " triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009, 116:317-328.
63. Kenny P.A., Bissell M.J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007, 117:337-345.
64. Ciarloni L., Mallepell S., Brisken C. Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci USA 2007, 104:5455-5460.
65. Rho J.Y., Wada-Kiyama Y., Onishi Y., Kiyama R., Sakuma Y. Expressional regulation of neuronal and cancer-related genes by estrogen in adult female rats. Endocr Res 2004, 30:257-267.
66. Britton D.J., Hutcheson I.R., Knowlden J.M., Barrow D., Giles M., McClelland R.A., et al. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006, 96:131-146.
67. Fan P., Yue W., Wang J.P., Aiyar S., Li Y., Kim T.H., et al. Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models. Endocrinology 2009, 150:2036-2045.
68. Jordan V.C., O'Malley B.W. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007, 25:5815-5824.
69. Santen R.J., Fan P., Zhang Z., Bao Y., Song R.X., Yue W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 2009, 74:586-594.
70. Fan M., Yan P.S., Hartman-Frey C., Chen L., Paik H., Oyer S.L., et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006, 66:11954-11966.
71. Frogne T., Benjaminsen R.V., Sonne-Hansen K., Sorensen B.S., Nexo E., Laenkholm A.V., et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009, 114:263-275.
72. Dick J.E. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
73. Dick J.E. Looking ahead in cancer stem cell research. Nat Biotechnol 2009, 27:44-46.
74. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
75. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
76. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313.
77. Farnie G., Clarke R.B., Spence K., Pinnock N., Brennan K., Anderson N.G., et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007, 99:616-627.
78. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
79. Schmidt C. Lapatinib study supports cancer stem cell hypothesis, encourages industry research. J Natl Cancer Inst 2008, 100:694-695.
80. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev 1998, 19:18-54.
81. Ali S.M., Harvey H.A., Lipton A. Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res 2003, 415:S132-S137.
82. Clark G.M., Sledge G.W., Osborne C.K., McGuire W.L. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987, 5:55-61.
83. Zhang X.H., Wang Q., Gerald W., Hudis C.A., Norton L., Smid M., et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78.
84. Diel I.J., Solomayer E.F., Costa S.D., Gollan C., Goerner R., Wallwiener D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
85. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284.
86. Emi Y., Kitamura K., Shikada Y., Kakeji Y., Takahashi I., Tsutsui S. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery 2002, 131:S217-S221.
87. Riethdorf S., Wikman H., Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008, 123:1991-2006.
88. Fehm T., Mueller V., Marches R., Klein G., Gueckel B., Neubauer H., et al. Tumor cell dormancy: implications for the biology and treatment of breast cancer. Apmis 2008, 116:742-753.
89. Wikman H., Vessella R., Pantel K. Cancer micrometastasis and tumour dormancy. Apmis 2008, 116:754-770.
90. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006, 12:5615-5621.
91. Braun S., Schlimok G., Heumos I., Schaller G., Riethdorf L., Riethmuller G., et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 2001, 61:1890-1895.
92. Pantel K., Schlimok G., Braun S., Kutter D., Lindemann F., Schaller G., et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993, 85:1419-1424.
93. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999, 140:4451-4458.
94. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
95. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
96. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s.
97. Guise T.A. Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 2009, 23:2117-2123.
98. Li Z., Schem C., Shi Y., Medina D., Zhang M. Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. Clin Exp Metastasis 2007, 25:389-400.
99. Bendre M.S., Gaddy-Kurten D., Mon-Foote T., Akel N.S., Skinner R.A., Nicholas R.W., et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002, 62:5571-5579.
100. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999, 103:197-206.
101. Davideau J.L., Sahlberg C., Thesleff I., Berdal A. EGF receptor expression in mineralized tissues: an in situ hybridization and immunocytochemical investigation in rat and human mandibles. Connect Tissue Res 1995, 32:47-53.
102. Ng K.W., Partridge N.C., Niall M., Martin T.J. Epidermal growth factor receptors in clonal lines of a rat osteogenic sarcoma and in osteoblast-rich rat bone cells. Calcif Tissue Int 1983, 35:298-303.
103. Guise T.A., Yoneda T., Yates A.J., Mundy G.R. The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab 1993, 77:40-45.
104. Ibbotson K.J., D'Souza S.M., Ng K.W., Osborne C.K., Niall M., Martin T.J., et al. Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science 1983, 221:1292-1294.
105. Ibbotson K.J., D'Souza S.M., Smith D.D., Carpenter G., Mundy G.R. EGF receptor antiserum inhibits bone resorbing activity produced by a rat Leydig cell tumor associated with the humoral hypercalcemia of malignancy. Endocrinology 1985, 116:469-471.
106. Zhu J., Jia X., Xiao G., Kang Y., Partridge N.C., Qin L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 2007, 282:26656-26664.
107. Normanno N., De Luca A., Aldinucci D., Maiello M.R., Mancino M., D'Antonio A., et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 2005, 12:471-482.
108. Qin L., Qiu P., Wang L., Li X., Swarthout J.T., Soteropoulos P., et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem 2003, 278:19723-19731.
109. Qin L., Partridge N.C. Stimulation of amphiregulin expression in osteoblastic cells by parathyroid hormone requires the protein kinase A and cAMP response element-binding protein signaling pathway. J Cell Biochem 2005, 96:632-640.
110. Cole J.A. Parathyroid hormone activates mitogen-activated protein kinase in opossum kidney cells. Endocrinology 1999, 140:5771-5779.
111. Guise T.A., Yin J.J., Taylor S.D., Kumagai Y., Dallas M., Boyce B.F., et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996, 98:1544-1549.
112. Southby J., Kissin M.W., Danks J.A., Hayman J.A., Moseley J.M., Henderson M.A., et al. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res 1990, 50:7710-7716.
113. Powell G.J., Southby J., Danks J.A., Stillwell R.G., Hayman J.A., Henderson M.A., et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991, 51:3059-3061.
114. Henderson M., Danks J., Moseley J., Slavin J., Harris T., McKinlay M., et al. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst 2001, 93:234-237.
115. Vargas S.J., Gillespie M.T., Powell G.J., Southby J., Danks J.A., Moseley J.M., et al. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J Bone Miner Res 1992, 7:971-979.
116. Cho Y.M., Lewis D.A., Koltz P.F., Richard V., Gocken T.A., Rosol T.J., et al. Regulation of parathyroid hormone-related protein gene expression by epidermal growth factor-family ligands in primary human keratinocytes. J Endocrinol 2004, 181:179-190.
117. Lorch G., Gilmore J.L., Koltz P.F., Gonterman R.M., Laughner R., Lewis D.A., et al. Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. Br J Cancer 2007, 97:183-193.
118. Richard V., Rosol T.J., Foley J. PTHrP gene expression in cancer: do all paths lead to Ets?. Crit Rev Eukaryot Gene Expr 2005, 15:115-132.
119. Gilmore J.L., Scott J.A., Bouizar Z., Robling A., Pitfield S.E., Riese D.J., et al. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat 2007, 110:493-505.
120. Lu X., Wang Q., Hu G., Van Poznak C., Fleisher M., Reiss M., et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009, 23:1882-1894.
121. MacLeod J.R., Yano S., Chattopadhyay N., Brown E.M. Extracellular calcium-sensing receptor transactivates the epidermal growth factor receptor by a triple-membrane-spanning signaling mechanism. Biochem Biophys Res Commun 2004, 320:455-460.
122. Gschwind A., Hart S., Fischer O.M., Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003, 22:2411-2421.
123. Normanno N., Morabito A., De Luca A., Piccirillo M.C., Gallo M., Maiello M.R., et al. Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer 2009, 16:675-702.
124. Albain K.S., Elledge R., Gradishar W.J., Hayes D.F., Rowinsky E., Hudis C., et al. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002, 76:S33.
125. von Minckwitz G., Jonat W., Fasching P., du Bois A., Kleeberg U., Luck H.J., et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005, 89:165-172.
126. Cristofanilli M., Valero V., Mangalik A., Royce M., Rabinowitz I., Arena F.P., et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010, 16:1904-1914.
127. Leary A.F., Drury S., Detre S., Pancholi S., Lykkesfeldt A.E., Martin L.A., et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010, 16:1486-1497.
128. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.